I wouldn’t doubt the FDA has stringent paperwork like that. I don’t know if this is something else from the SeekingAlpha 2022 article a couple months ago where they repeated the same thing but in the June of 2020 PR SBFM said they already filed (IND Fast Track with IND status) and this article from April of 2022 just states they anticipate filing. So wtf, is it the same thing or a different application? Never ever do they clarify things, except once in a blue moon on Twitter instead of a filing or PR.
The patent dates don’t match either. Initially it was 2033, to which they sometimes said 2034 (only in the USA), as well as 2040, which might be for another country which confuses me if they are talking about FDA approval. I think one of their patents is 2040 (another country I believe) for the same patent filed in the USA, with the USA one having an expiration of 2033.
This part gave me a chuckle
Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.
Sunshine Biopharma Files A Patent Application For A New Coronavirus COVID-19 Treatment June 3, 2020
MONTREAL, QC / ACCESSWIRE / June 3, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer today announced that it has filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Sunshine's patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
"The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral 'polyproteins,' pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins' at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase'. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections," said Dr. Slilaty.
News 
Market Data 
Discover 
